Skip to content

Post-operative Haloperidol Versus Placebo for Prevention of Post-operative Delirium After Acute Hip Surgery

Randomised Double-blind Placebo-controlled Study of Post-operative Haloperidol Versus Placebo for Prevention of Post-operative Delirium After Acute Hip Surgery

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00250237
Enrollment
220
Registered
2005-11-08
Start date
2005-11-30
Completion date
2009-02-28
Last updated
2009-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip Fracture, Post-Operative Delirium

Keywords

Post-operative delirium, hip fracture

Brief summary

In this study the investigators want to determine if treatment with haloperidol direct post-operatively after acute hip surgery in high risk patients protects against developing a post-operative delirium.

Detailed description

A post-operative delirium is a serious and frequent (35-65%) complication with high morbidity and mortality in high risk patients. In this study we investigate whether we can prevent a delirium from occuring after surgery in patients with a hip fracture of 75 years of age and older. It's a randomised double-blind single centre placebo-controlled study of haloperidol versus placebo.

Interventions

DRUGHaloperidol

Haloperidol 1mg twice daily during 72hours

DRUGplacebo

Placebo 1mg twice daily during 72hours

Sponsors

Bronovo Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
75 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Hip fracture * 75 years and older

Exclusion criteria

* Contra-indications for the use of haloperidol * Pre-operative delirium * Pre-operative use of haloperidol

Design outcomes

Primary

MeasureTime frame
Incidence of post-operative delirium72 hours post surgery

Secondary

MeasureTime frame
Length of staydays
Complicationsduring hospitalization

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 5, 2026